Safety Study of TAK-700 in Subjects With Prostate Cancer.

Prostatic Neoplasms Clinical Trial

— TAK-700  

Official title:

A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00569153
• Other study ID #: TAK-700_201
• Secondary ID: TAK-700-201
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: December 4, 2007
• Last updated: July 1, 2013
• Start date: April 2008
• Est. completion date: February 2013

Study information

• Verified date: June 2013
• Source: Millennium Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 123
• Est. completion date: February 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is male and at least 18 years of age.

• Subject has histologically- or cytologically-confirmed prostate adenocarcinoma with metastatic, progressive disease while on androgen deprivation therapy.

• Subject has radiograph-documented (computed tomography, magnetic resonance imaging or x-ray) metastatic disease.

• Subject has undergone orchiectomy or is expected to continue receiving luteinizing hormone-releasing hormone analogue therapy, and has a testosterone level of <50 ng/dL at screening.

• Subject has discontinued all antiandrogen therapy (within 30 days for flutamide and within 6 weeks for all others) prior to their first dose of study drug.

• Subject has a prostate-specific antigen level =5 ng/mL.

• Subject meets all screening laboratory values as specified in the protocol.

• Subject has a screening ejection fraction that is above the lower limit of the institutional normal range.

• Subject has ECOG performance status of 0 to 2.

• Subject has normal or, in the opinion of the investigator, clinically insignificant, physical examination findings, ECG and chest x-ray results.

• Subjects, even if surgically sterilized (ie, status postvasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.

Exclusion Criteria:

• Subject has known hypersensitivity to TAK-700 or related compounds.

• Subject has received prior therapy with aminoglutethimide or ketoconazole within 30 days prior to the first dose of study drug.

• Subject has received prior chemotherapy for prostate cancer.

• Subject has received any investigational compound within 30 days prior to first dose of study drug.

• Subject has received prior herbal product known to decrease prostate-specific antigen levels (eg, Saw Palmetto, PC-SPES) within 30 days prior to the first dose of study drug.

• Subject has received radiation therapy for prostate cancer within 30 days prior to first dose of study drug.

• Chronic therapy with oral or other systemically administered corticosteroids, such as prednisone, within 30 days prior to Screening. Chronic therapy is defined as the use of corticosteroids for more than 7 days within a 30-day period.

• Subject has current spinal cord compression, current bilateral hydronephrosis, or current bladder neck outlet obstruction.

• Subject has a history of adrenal insufficiency.

• Subject has a history of myocardial infarction, ischaemic symptomatic heart disease, cardiac arrhythmias or thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 12 months prior to first dose of study drug.

• Subject has any symptoms which the investigator deems related to prostate cancer, i.e., bone pain, pelvic pain.

• Subject has a history of congestive heart failure (New York Heart Association Class II or greater.

• Subject has history of another malignancy other than basal cell carcinoma or state 1 squamous cell carcinoma of the skin, within the last 5 years.

• Subject has uncontrolled hypertension.

• Subject is known to have HIV infection, chronic Hepatitis B or C or any other serious medical condition or psychiatric illness that might affect life expectancy or make it difficult to successfully manage and follow the subject according to protocol.

• Subject is unable to understand verbal or written English or any other language for which a certified translation of the institutional review board (IRB)-approved informed consent has been provided.

• Subject is unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostatic Neoplasms

Intervention

Drug:
• TAK-700
Phase 1 portion of study: TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event. Phase 2 portion of study: Patients will receive one of 4 treatments: TAK-700 at 300 mg twice/day TAK-700 at 400 mg and 5 mg prednisone twice/day TAK-700 at 600 mg and 5 mg prednisone twice/day TAK-700 at 600 mg once/day in the morning

Locations

Country	Name	City	State
United States	South Florida Medical Research	Aventura	Florida
United States	USC Westside Prostate Cancer Center	Beverly Hills	California
United States	Gabrail Cancer Center	Canton	Ohio
United States	Northwestern University Medical Center	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	University of Chicago Comprehensive Cancer Center	Chicago	Illinois
United States	University of Chicago Pharmacy	Chicago	Illinois
United States	Cleveland Clinic	Cleveland	Ohio
United States	Taussig Cancer Institute	Cleveland	Ohio
United States	Hematology/Oncology Associates of Central New York	East Syracuse	New York
United States	Evanston Hospital	Evanston	Illinois
United States	Kellogg Pharmacy - Evanston Hospital	Evanston	Illinois
United States	NorthShore University HealthSystem	Evanston	Illinois
United States	Florida Cancer Specialists	Fort Myers	Florida
United States	Kellogg Cancer Care Center	Glenview	Illinois
United States	The Angeles Clinic and Research Institute	Los Angeles	California
United States	University of Southern California	Los Angeles	California
United States	USC Norris Comprehensive Cancer Center	Los Angeles	California
United States	Tennessee Oncology	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of TAK-700 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.		Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.	Yes
Secondary	Efficacy and pharmacokinetics (PSA response and/or objective disease response)		Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.	No